Immunological Landscape of HER-2 Positive Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jul 9

PMID 35804943

Authors

Santiago Moragon

Cristina Hernando

Maria Teresa Martinez-Martinez

Marta Tapia

Belen Ortega-Morillo

Ana Lluch

Begona Bermejo

Juan Miguel Cejalvo

Affiliations

Soon will be listed here.

Abstract

Understanding the biological aspects of immune response in HER2+ breast cancer is crucial to implementing new treatment strategies in these patients. It is well known that anti-HER2 therapy has improved survival in this population, yet a substantial percentage may relapse, creating a need within the scientific community to uncover resistance mechanisms and determine how to overcome them. This systematic review indicates the immunological mechanisms through which trastuzumab and other agents target cancer cells, also outlining the main trials studying immune checkpoint blockade. Finally, we report on anti-HER2 vaccines and include a figure exemplifying their mechanisms of action.

Citing Articles

Investigating tumor immunogenicity in breast cancer: deciphering the tumor immune response to enhance therapeutic approaches.

Naji O, Ghouzlani A, Rafii S, Sadiqi R, Kone A, Harmak Z Front Immunol. 2024; 15:1399754.

PMID: 39507526 PMC: 11538072. DOI: 10.3389/fimmu.2024.1399754.

Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study.

Degirmenci M, Diniz G, Kahraman D, Sahbazlar M, Koral L, Varol U Breast Cancer (Dove Med Press). 2024; 16:645-655.

PMID: 39355199 PMC: 11444060. DOI: 10.2147/BCTT.S470570.

Unveiling the Immune Microenvironment's Role in Breast Cancer: A Glimpse into Promising Frontiers.

Kotsifaki A, Alevizopoulos N, Dimopoulou V, Armakolas A Int J Mol Sci. 2023; 24(20).

PMID: 37895012 PMC: 10607694. DOI: 10.3390/ijms242015332.

References

Dieras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J . Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(6):732-742. PMC: 5531181. DOI: 10.1016/S1470-2045(17)30312-1. View

Shimizu C, Mogushi K, Morioka M, Yamamoto H, Tamura K, Fujiwara Y . Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab. Breast Cancer. 2015; 23(4):624-32. DOI: 10.1007/s12282-015-0614-y. View

Weis L, Tolaney S, Barrios C, Barroso-Sousa R . Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?. NPJ Breast Cancer. 2021; 7(1):120. PMC: 8437983. DOI: 10.1038/s41523-021-00328-3. View

Emens L, Esteva F, Beresford M, Saura C, De Laurentiis M, Kim S . Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020; 21(10):1283-1295. DOI: 10.1016/S1470-2045(20)30465-4. View

Modi S, Saura C, Yamashita T, Park Y, Kim S, Tamura K . Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2019; 382(7):610-621. PMC: 7458671. DOI: 10.1056/NEJMoa1914510. View

Gennari A, Andre F, Barrios C, Cortes J, de Azambuja E, DeMichele A . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12):1475-1495. DOI: 10.1016/j.annonc.2021.09.019. View

Hashimoto K . CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development. Cancers (Basel). 2021; 13(10). PMC: 8150789. DOI: 10.3390/cancers13102288. View

Tan T, Chan J, Kamis S, Dent R . What is the role of immunotherapy in breast cancer?. Chin Clin Oncol. 2018; 7(2):13. DOI: 10.21037/cco.2018.04.01. View

Patil R, Clifton G, Holmes J, Amin A, Carmichael M, Gates J . Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J Am Coll Surg. 2010; 210(2):140-7. DOI: 10.1016/j.jamcollsurg.2009.10.022. View

10.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G . Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019; 20(3):371-382. DOI: 10.1016/S1470-2045(18)30812-X. View

11.

Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S . Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. Cancer Treat Rev. 2017; 57:8-15. DOI: 10.1016/j.ctrv.2017.04.005. View

12.

Iwata T, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T . A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Mol Cancer Ther. 2018; 17(7):1494-1503. DOI: 10.1158/1535-7163.MCT-17-0749. View

13.

Scaltriti M, Verma C, Guzman M, Jimenez J, Parra J, Pedersen K . Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2008; 28(6):803-14. DOI: 10.1038/onc.2008.432. View

14.

Koski G, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E . A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother. 2011; 35(1):54-65. PMC: 3241864. DOI: 10.1097/CJI.0b013e318235f512. View

15.

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman W . Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19(6):307-325. DOI: 10.1038/s41568-019-0144-6. View

16.

Oberg H, Kellner C, Gonnermann D, Sebens S, Bauerschlag D, Gramatzki M . Tribody [(HER2)xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. Front Immunol. 2018; 9:814. PMC: 5916959. DOI: 10.3389/fimmu.2018.00814. View

17.

Dieci M, Conte P, Bisagni G, Brandes A, Frassoldati A, Cavanna L . Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. Ann Oncol. 2019; 30(3):418-423. PMC: 6442655. DOI: 10.1093/annonc/mdz007. View

18.

Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K . Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013; 4(10):1592-605. PMC: 3858548. DOI: 10.18632/oncotarget.1148. View

19.

Song P, Mansur A, Dugger K, Davis T, Howard G, Yankeelov T . CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro. Cancer Cell Int. 2020; 20(1):544. PMC: 7654187. DOI: 10.1186/s12935-020-01625-w. View

20.

Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N . Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol. 1997; 15(4):1354-66. DOI: 10.1200/JCO.1997.15.4.1354. View